BACKGROUND: Many low-risk patients with pneumonia are hospitalized despite recommendations to treat such patients in the outpatient setting.
OBJECTIVE: To identify the factors associated with the hospitalization of low-risk patients with pneumonia.
METHODS: We analyzed data collected by retrospective chart review for 1,889 low-risk patients (Pneumonia Severity Index [PSI] risk
classes I to III without evidence of arterial oxygen desaturation) enrolled in a cluster-randomized trial conducted in 32
emergency departments.
RESULTS: Overall, 845 (44.7%) of all low-risk patients were treated as inpatients. Factors independently associated with an increased
odds of hospitalization included PSI risk classes II and III, the presence of medical or psychosocial contraindications to
outpatient treatment, comorbid conditions that were not contained in the PSI (cognitive impairment, history of coronary artery
disease, diabetes mellitus, or pulmonary disease), multilobar radiographic infiltrates, and home therapy with oxygen, corticosteroids,
or antibiotics before presentation. While 32.8% of low-risk inpatients had a contraindication to out-patient treatment and
47.1% had one or more preexisting treatments, comorbid conditions, or radiographic abnormalities not contained in the PSI,
20.1% had no identifiable risk factors for hospitalization other than PSI risk class II or III.
CONCLUSIONS: Hospital admission appears justified for one-third of low-risk inpatients based upon the presence of one or more contra-indications
to outpatient treatment. At least one-fifth of low-risk inpatients did not have a contraindication to outpatient treatment
or an identifiable risk factor for hospitalization, suggesting that treatment of a larger proportion of such low-risk patients
in the outpatient setting could be achieved without adversely affecting patient outcomes.
Key words pneumonia - community-acquired infections - patient admission - risk factors - emergency service, hospital
This research was conducted as part of the project, Guideline to Improve Quality of Initial Pneumonia Care, funded by the
Agency for Healthcare Research and Quality (grant number R01 HS10049). Dr. M. J. Fine was supported in part by a K-24 career
development award from the National Institute of Allergy and Infectious Diseases (5K24 A101769). Dr. J. Labarere was supported
by a grant from the Egide foundation, Paris, France (Programme Lavoisier), and by the Grenoble University Hospital (DRC, CHU
Grenoble).